Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical Conferences
September 27, 2021 at 09:00 AM EDT
REDWOOD CITY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of new clinical data on ADVM-022 intravitreal (IVT) injection gene therapy from the OPTIC trial in wet age-related macular degeneration (wet AMD) and the INFINITY trial in diabetic macular edema (DME) at upcoming medical conferences. Adverum is planning clinical development of ADVM-022 at the 2 x 10^11 vg/eye and a lower dose in patients with wet AMD. As previously disclosed, the company is no longer planning to develop ADVM-022 in DME.
Presentation of New Long-term OPTIC Data in Wet AMD
Presentation of INFINITY Data in DME
Encore Presentation of OPTIC Data in Wet AMD
Adverum intends to issue press releases concurrent with the presentation at Retina Society on October 1 and at ASRS on October 9, and plans to post all three data presentations on the Publications page in the Pipeline section of the company’s website.
About Adverum Biotechnologies